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sis) on the basis of previous experience showing that
most cases of rejection occurred before this time
interval.
With regard to the rate of side-eﬀects, thismay be due to
the fact that a high dose of interferon was used by the
authors, while ribavirin was avoided in most cases. Con-
versely, and as reported in our paper, we carefully assessed
the type and dosage of pegylated interferon (i.e., peginter-
feron alpha-2a, 135 lg/weekly) due to the presence of
chronic renal failure and individually tailored the dosage
of ribavirin to avoid even more severe anaemia which
was controlled by administration of erythropoietin. This
strategy resulted in a strong anti-viral eﬀect and avoided,
in most instances, major side-eﬀects and, probably, also
rejection.
To better deﬁne the use of graftectomy, further stud-
ies, on a larger series, are necessary focusing on compar-
isons between the rejection rates in patients receiving
interferon and those not receiving interferon. On the
basis of our experience and available data, anti-viraltreatment should, in our opinion, be delayed until 12
months after graft loss.
We wish to thank Dr. Sperl who gave us the
opportunity to emphasize these points which complete
our results and would, no doubt, contribute to
improving the pharmacological approach with pegylat-
ed interferon and ribavirin in this particular category
of patients.
Maria Rendina
Antonio Francavilla
Department of Emergency and Organ Transplant,
Section of Gastroenterology, University of Bari,
Piazza G. Cesare 11, 70124 Bari, Italy
E-mail address: mariarendina@virgilio.it
Antonio Schena
Francesco Paolo Schena
Department of Emergency and Organ Transplant,
Section of Nephrology, University of Bari,
Bari, Italy
doi:10.1016/j.jhep.2008.06.001Neonatal classical galactosaemia presenting as citrin deﬁciencyTo the Editor:
Wereadwith interest the recent study byFeillet et al. [1].
This is an elegant paper which eloquently analyses and ex-
plains what turned out to be a secondarymetabolic abnor-
mality. We agree that neonatal citrin deﬁciency needed to
be considered as a diﬀerential diagnosis, albeit a rare one.
Clinical presentation of citrin deﬁciency is heterogeneous
andnon speciﬁc andgalactosaemia is awell recognisedbio-
chemical feature. Although citrullinaemia is common it is
not speciﬁc, may be absent and the diagnosis of citrin deﬁ-
ciency today largely depends on mutation analysis.
In neonatal liver failure, in particular, it is often diﬃcult
to distinguish between what are primary metabolic abnor-
malities causing liver dysfunction and secondary abnor-
malities as a result of liver dysfunction. The situation can
becomeparticularly complicatedwhen there has been a de-
lay in diagnosis or partial treatment as in this case.
In the setting of such a complexmulti-systemic disease,
it is important to have some simple guiding principles.
Galactosaemia is one of the commonest causes of neona-
tal liver failure. A galactose free diet should be given to all
children with neonatal liver failure until galactosaemia
has been speciﬁcally excluded by enzyme analysis. Agalactose challenge is neither appropriate nor necessary
as a diagnostic test for galactosaemia and is not without
risk.Anapproach to the diagnosis or exclusion of possible
galactosaemia when the situation is complicated is sum-
marised in a recent review [2].
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